SCHEMBL2435950

SCHEMBL2435950

C#Cc1cccc(Nc2ncnc3cc(OCCO)c(OCCO)cc23)c1.C#Cc1cccc(Nc2ncnc3cc(OCCOC)c(OCCO)cc23)c1

nearest known ligand 1.00 ✓ in ChEMBL — recovers established targets

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EGFR P00533 15/20 1.00
ERBB2 P04626 7/20 0.90
GAK O14976 4/20 0.90
KDR P35968 3/20 0.90
ILK Q13418 2/20 0.90
FLT1 P17948 2/20 0.90
RIPK2 O43353 2/20 0.90
BUB1 O43683 2/20 0.90
STK10 O94804 2/20 0.90
ABL1 P00519 2/20 0.90
LCK P06239 2/20 0.90
LYN P07948 2/20 0.90
RET P07949 2/20 0.90
SRC P12931 2/20 0.90
FGFR2 P21802 2/20 0.90
FECH P22830 2/20 0.90
FLT3 P36888 2/20 0.90
MAP3K1 Q13233 2/20 0.90
PLK4 O00444 1/20 0.90
CIT O14578 1/20 0.90

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1507409 1.00 EGFR (1.00) EGFRERBB2GAKKDRILK
SCHEMBL1507627 1.00 EGFR (1.00) EGFRERBB2GAKKDRILK
SCHEMBL29354959 1.00 EGFR (1.00) EGFRERBB2GAKKDRILK
Hydrochloric Acid SCHEMBL1507689 0.99 EGFR (0.98) EGFRERBB2GAKKDRILK
Hydrochloric Acid SCHEMBL1507491 0.99 EGFR (0.98) EGFRERBB2GAKKDRILK
Erlotinib SCHEMBL29120903 0.95 EGFR (0.96) EGFRERBB2GAKKDRILK
Erlotinib SCHEMBL3667407 0.95 EGFR (1.00) EGFRERBB2GAKKDRILK
Erlotinib SCHEMBL8413 0.95 EGFR (1.00) EGFRERBB2GAKKDRILK
Erlotinib SCHEMBL29351329 0.95 EGFR (1.00) EGFRERBB2GAKKDRILK
Erlotinib SCHEMBL30362833 0.95 EGFR (1.00) EGFRERBB2GAKKDRILK

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2011112588-A2 COMPOSITIONS AND METHODS FOR TREATING INFLAMMATORY DISORDERS CASE WESTERN RESERVE UNIVERSITY (US) 2011-09-15 WO disclosed